Figure 7
Effect of systemic anti-VEGF antibodies on FGF-2–induced angiogenesis in vivo. A, Gross photographs of three representative Matrigel implants containing FGF-2 combined with systemic treatment with nonimmune chicken IgY (Control IgY) and anti-VEGF (Anti-VEGF IgY). Note the lack of associated skin vessel dilation and Matrigel coloration in the anti-VEGF group. B, Histologic evaluation of the stromal and angiogenic response induced by FGF-2 with control and anti-VEGF systemic treatments. Hematoxylin and eosin (H&E) and antimouse type IV collagen (collagen IV) are presented for control IgY (a and b) and anti-VEGF IgY (c and d). Matrigel (MG), stromal interface (I), and dermis (D) are indicated. Inset, Quantification of the angiogenic response in the control and anti-VEGF groups (n = 10) is expressed as average vessels per field ± sem. Statistical difference from control IgG: * p < 0.001.
